Characterization of biased receptor signaling has ushered in opportunities for unprecedented control of G-protein-coupled receptors. Elucidation of distinct M1 muscarinic acetylcholine receptor signaling pathways and development of biased ligands may offer novel and safer Alzheimer’s disease therapeutics.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Moran, S. P., Maksymetz, J. & Conn, P. J. Trends Pharmacol. Sci. 40, 1006–1020 (2019).
Bradley, S. J. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-019-0453-9 (2020).
Bender, A. M., Jones, C. K. & Lindsley, C. W. ACS Chem. Neurosci. 8, 435–443 (2017).
Voss, T. et al. Alzheimers Dement. (N. Y.) 4, 173–181 (2018).
Sako, Y. et al. Neuropsychopharmacology 44, 950–960 (2019).
Kurimoto, E. et al. J. Pharmacol. Exp. Ther. 364, 28–37 (2018).
Marlo, J. E. et al. Mol. Pharmacol. 75, 577–588 (2009).
Moran, S. P. et al. Sci. Signal. 12, eaax2057 (2019).
Moran, S. P. et al. Neuropsychopharmacology 43, 1763–1771 (2018).
Moran, S. P. et al. ACS Chem. Neurosci. 9, 2218–2224 (2018).
The authors declare no competing interests
Rights and permissions
About this article
Cite this article
Moran, S.P., Conn, P.J. Leveraging bias to your advantage. Nat Chem Biol 16, 226–227 (2020). https://doi.org/10.1038/s41589-020-0468-2